Treatments and methods for increasing dopamine
AssigneeOxford University Innovation Limited
InventorsYanfeng Zhang, Stephanie J. Cragg
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for increasing dopamine levels in a subject. The present invention also relates to the treatment of condition or disorder in which reduced levels of dopamine are implicated, and agents for use in such treatments.
Claims25
A nicotinic acetylcholine receptor antagonist/blocker, or a pharmaceutically acceptable salt thereof, for use in the treatment of a condition or disorder in which reduced levels of dopamine in the CNS are implicated.
A nicotinic acetylcholine receptor (nAChR) antagonist/blocker, for the use according to any one of the preceding claims, wherein administration of the nicotinic acetylcholine receptor antagonist/blocker promotes dopamine release in the striatum.
A nicotinic acetylcholine receptor (nAChR) antagonist/blocker, for the use according to any one of the preceding claims, wherein administration of the nicotinic acetylcholine receptor antagonist/blocker promotes dopamine release in the dorsal striatum, ventral striatum, ventral tegmental area, basal ganglia and/or the substantia nigra.
A nicotinic acetylcholine receptor (nAChR) antagonist/blocker, for the use according to any one of the preceding claims, wherein the condition or disorder is one in which reduced levels of dopamine in the brain are implicated.
A nicotinic acetylcholine receptor (nAChR) antagonist/blocker, for the use according to any one of the preceding claims, wherein the condition or disorder is one in which reduced levels of dopamine in the striatum are implicated.
A nicotinic acetylcholine receptor (nAChR) antagonist/blocker, for the use according to any one of the preceding claims, wherein the condition or disorder is one in which reduced levels of dopamine in the dorsal striatum, ventral striatum, ventral tegmental area, basal ganglia and/or the substantia nigra are implicated.
A nicotinic acetylcholine receptor (nAChR) antagonist/blocker, for the use according to any one of the preceding claims, wherein the condition or disorder is selected from dopamine deficiency, addiction (including binge eating, nicotine addiction and alcohol addiction), Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), bipolar disorder, dopa-responsive dystonia and DRD-plus, Huntington's disease, multiple sclerosis, obsessive compulsive disorder (OCD), Parkinson's disease (including resting tremor in Parkinson's disease), schizophrenia, tics (i.e. a repetitive involuntary movement or sound), Tourette's syndrome, depression and reward deficiency syndrome.
A nicotinic acetylcholine receptor (nAChR) antagonist/blocker, for use according to any one of the preceding claims, wherein the condition or disorder is selected from Parkinson's Disease or ADHD.
A nicotinic acetylcholine receptor (nAChR) antagonist/blocker, for use according to any one of the preceding claims, wherein the condition or disorder is Parkinson's Disease.
A nicotinic acetylcholine receptor (nAChR) antagonist/blocker, for the use according to any one of the preceding claims, wherein the nicotinic acetylcholine receptor antagonist/blocker is selected from Dihydro-β-erythroidine (DHβE), mecamylamine, bPiDDP (1,1′-(1, 12-Dodecanediyl)bis[3-methylpyridinium]dibromide), methyllycaconitine, MG 624 (N,N, N-Triethyl-2-[4-(2-phenylethenyl)phenoxy]ethanaminium iodide), SR 16584 (1,3-Dihydro-1-(3-exo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-2H-indol-2-one), Catestatin, Chlorisondamine diiodide, 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), Chlorisondamine, α-conotoxins (e.g. ACV 1, AulB, El, Iml, MII, PIA, PnlA), A 85380 (3-[(2S)-2-Azetidinylmethoxy]-pyridine, ABT 089 (2-Methyl-3-[(2S)-pyrrolidinylmethoxy]pyridine), ABT 594 ((R)-5-(Azetidin-2-ylmethoxy)-2-chloropyridine), Dianicline ((5aS,8S,10aR)-5a,6,9,10-Tetrahydro-7H, 11H-8,10a-methanopyrido[2′,3′:5,6]pyrano[2,3-d]azepine), RJR 2403 ((E)-N-Methyl-4-(3-pyridinyl)-3-buten-1-amine), TC 2559 (4-(5-ethoxy-3-pyridinyl)-N-methyl-(3E)-3-buten-1-amine), Varenicline (7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine), hexamethonium bromide, tubocurarine chloride, α-bungarotoxin, COG 133, D-amphetamine sulfate, PAMP-20, or a pharmaceutically acceptable salt or derivative thereof;
- optionally wherein the nicotinic acetylcholine receptor antagonist/blocker is selected from Dihydro-β-erythroidine (DhBE), mecamylamine, bPiDDP, methyllycaconitine, MG 624, SR 16584, Catestatin, Chlorisondamine diiodide, 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), Chlorisondamine, α-conotoxins (e.g. ACV 1, AulB, El, Iml, MII, PIA, PnlA), A 85380 dihydrochloride (3-[(2S)-2-Azetidinylmethoxy]-pyridine dihydrochloride, ABT 089 (2-Methyl-3-[(2S)-pyrrolidinylmethoxy]pyridine), ABT 594 ((R)-5-(Azetidin-2-ylmethoxy)-2-chloropyridine), Dianicline ((5aS,8S,10aR)-5a,6,9,10-Tetrahydro-7H, 11H-8,10a-methanopyrido[2′,3′:5,6]pyrano[2,3-d]azepine), RJR 2403 ((E)-N-Methyl-4-(3-pyridinyl)-3-buten-1-amine), TC 2559 (4-(5-ethoxy-3-pyridinyl)-N-methyl-(3E)-3-buten-1-amine), Varenicline (7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine tartrate), or a pharmaceutically acceptable salt or derivative thereof.
A nicotinic acetylcholine receptor (nAChR) antagonist/blocker, for the use according to any one of the preceding claims, wherein the nicotinic acetylcholine receptor antagonist/blocker is selected from Dihydro-β-erythroidine (DhBE), mecamylamine, bPiDDP, methyllycaconitine, MG 624, SR 16584, Catestatin, Chlorisondamine diiodide, 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), Chlorisondamine and α-conotoxins (e.g. ACV 1, AulB, El, Iml, MII, PIA, PnlA), or a pharmaceutically acceptable salt or derivate thereof.
A nicotinic acetylcholine receptor (nAChR) antagonist/blocker for the use according to any one of the preceding claims, wherein the nicotinic acetylcholine receptor antagonist/blocker is selected from Dihydro-β-erythroidine (DhBE), mecamylamine, Chlorisondamine diiodide, 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), Chlorisondamine, or a pharmaceutically acceptable salt or derivate thereof.
A nicotinic acetylcholine receptor (nAChR) antagonist/blocker, for the use according to any one of the preceding claims, wherein the nicotinic acetylcholine receptor is selected from DHβE and mecamylamine.
A nicotinic acetylcholine receptor (nAChR) antagonist/blocker for the use according to any one of the preceding claims, wherein the nicotinic acetylcholine receptor antagonist/blocker is selective for the α4β2 receptor.
A nicotinic acetylcholine receptor (nAChR) antagonist/blocker, for the use according to any one the preceding claims, wherein the nicotinic acetylcholine receptor (nAChR) antagonist/blocker is administered orally, nasally, intraperitoneally, intracerebroventricularly, intrathecally, intracranially, subcutaneously, or intravenously.
A nicotinic acetylcholine receptor (nAChR) antagonist/blocker, for the use according to any one the preceding claims, wherein the nicotinic acetylcholine receptor (nAChR) antagonist/blocker is administered directly to the CNS.
A nicotinic acetylcholine receptor (nAChR) antagonist/blocker, for the use according to any one the preceding claims, wherein the nicotinic acetylcholine receptor (nAChR) antagonist/blocker is administered via intraperitoneal injection, intravenous injection, local infusion to the CNS or direct injection to the CNS.
A nicotinic acetylcholine receptor (nAChR) antagonist/blocker, for use in increasing the level of dopamine in the CNS.
The use of a nicotinic acetylcholine receptor (nAChR) antagonist/blocker, or a pharmaceutically acceptable salt thereof, in increasing the level of dopamine in the CNS.
A method of treating a condition or disorder in which reduced levels of dopamine in the CNS are implicated, said method comprising administering to a subject in need thereof a therapeutically effective amount of a nicotinic acetylcholine receptor (nAChR) antagonist/blocker or a pharmaceutically acceptable salt thereof.
A method of increasing the level of dopamine in the CNS of a subject, the method comprising administering a therapeutically effective amount nicotinic acetylcholine receptor (nAChR) antagonist/blocker to the subject.
A pharmaceutical composition which comprises a nicotinic acetylcholine receptor antagonist/blocker, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, for use in the treatment of a condition or disorder in which reduced levels of dopamine in the CNS are implicated.
Dependencies are inferred from the claim text.